Restricted accessResearch articleFirst published online 2025-12
Effectiveness of combined targeted and hormonal therapies for post-menopausal women with hormone receptor-positive and HER2-negative advanced breast cancer: A systematic review and meta-analysis of RCTs
we aim to synthesize available evidence on the effectiveness of hormonal plus targeted therapies for post-menopausal women with hormone receptor-positive and HER2-negative advanced breast cancer.
Data Sources and Methods
We searched the following databases: Medline, PubMed, Cochrane Library, CINAHL, Web of Science, Scopus, and African Journal. Only studies that investigated the effectiveness of hormonal therapy combined with targeted therapy for HR+/HER2- advanced breast cancer treatment were included. The outcomes were progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). A random-effect meta-analysis model was employed. Statistical analysis was performed using Comprehensive Meta-analysis version 3.
Results
24 studies were included in the meta-analysis with an overall sample size of 7635. Median PFS, OS and ORR were found to be significantly increased in the combination group compared to hormonal monotherapy [SMD = 6.072 (95% CI = 3.785–8.360), p < 0.001], [SMD = 1.614 (95% CI = 0.139–3.089), p = 0.032] and [OR = 1.584 (CI 1.134–2.213), p = 0.007] respectively. Subgroup analysis showed a significant difference in PFS and ORR between patients who received “hormonal therapy + CDK4/6 inhibitors” vs hormonal therapy only [SMD = 6.015 (CI 3.069–8.960), p < 0.001], (OR = 1.828 (CI 1.030–3.243), p = 0.039] respectively.
Conclusion
Compared with hormonal monotherapy, targeted plus hormonal therapy significantly improves PFS, OS and ORR in postmenopausal women with HR+/HER2- advanced breast cancer.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71: 209–249.
3.
HortobagyiGNDe La Garza SalazarJPritchardK, et al.The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer2005; 6: 391–401.
4.
GhonchehMPournamdarZSalehiniyaH. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev2016; 17: 43–46.
5.
MomenimovahedZSalehiniyaH.Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press)2019; 11: 151–164.
Al-AzriMAl-AwisiHAl-RasbiS, et al.Psychosocial impact of breast cancer diagnosis among omani women. Oman Med J2014; 29: 437–444.
8.
IddrisuMAziatoLDedeyF. Psychological and physical effects of breast cancer diagnosis and treatment on young Ghanaian women: a qualitative study. BMC Psychiatry2020; 20: 353.
9.
YamauchiHKitanoAFukudaT. Socioeconomic impact of breast cancer survivors. J Clin Oncol2014; 32: e20611.
10.
WaksAGWinerEP. Breast cancer treatment. JAMA2019; 321: 316.
11.
HigginsMJBaselgaJ. Targeted therapies for breast cancer. J Clin Invest2011; 121: 3797–3803.
PolyakK. Heterogeneity in breast cancer. J Clin Invest2011; 121: 3786–3788.
14.
CardosoFSpenceDMertzS, et al.Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast2018; 39: 131–138.
15.
PerezEA. Treatment strategies for advanced hormone receptor positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resist Updat2016; 24: 13–22.
16.
WangJCaiLSongY, et al.Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). Eur J Cancer2023; 184: 73–82.
17.
YamamotoYIshikawaTHozumiY, et al.Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. BMC Cancer2013; 13: 239.
18.
MehtaRSBarlowWEAlbainKS, et al.Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med2019; 380: 1226–1234. Erratum in: N Engl J Med 2019; 380(23): 2282.
19.
KropIAbramsonVColleoniM, et al.A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer. Clin Cancer Res2020; 26: 6149–6157.
20.
JagerADe VriesEGEDer Houven Van OordtCWM, et al.A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging. Breast Cancer Res2020; 22: 97.
21.
Di LeoAJerusalemGPetruzelkaL, et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol2010; 28: 4594–4600. Erratum in: J Clin Oncol 2011; 29(16): 2293.
22.
RobertsonJFRBondarenkoIMTrishkinaE, et al.Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (falcon): an international, randomised, double-blind, phase 3 trial. Lancet2016; 388: 2997–3005.
23.
ChiaSGradisharWMauriacL, et al.Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol2008; 26: 1664–1670.
24.
BøttcherTMColdSJensenAB. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of effectiveness and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib. Acta Oncol2019; 58: 147–153.
25.
LiYZhangHMerkherY, et al.Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol2022; 15: 121.
26.
MeiselJLVenurVAGnantM, et al.Evolution of targeted therapy in breast cancer: where precision medicine began. Am Soc Clin Oncol Educ Book2018; 38: 78–86.
27.
DaiQWangYLiaoM, et al.Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis. Ann Palliat Med2022; 11: 3727–3742.
28.
ChanchanGXiangyuSFangfangS, et al.The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: a meta-analysis of randomized-control trials. PLOS ONE2018; 13: e0204202.
29.
ZhangTFengFZhaoW, et al.Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis. Cancer Manag Res2018; 10: 5869–5880.
30.
AlbanellJMartínezMTRamosM, et al.Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014–12 (FLIPPER). Eur J Cancer2022; 161: 26–37.
31.
AndréFCiruelosEMJuricD, et al.Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol2021; 32: 208–217.
32.
GuarneriVGiorgiCACinieriS, et al.Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: final results of the phase III randomised MAIN-A (MAINtenance afinitor) trial. Eur J Cancer2021; 154: 21–29.
33.
KornblumNZhaoFManolaJ, et al.Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol2018; 36: 1556–1563.
34.
MooreHCFBarlowWESomloG, et al.A randomized trial of fulvestrant, everolimus, and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222. Clin Cancer Res2022; 28: 611–617.
35.
SackettDLRosenbergWMGrayJA, et al.Evidence based medicine. What it is and what it isn’t. Br Med J1996; 312: 71–72.
36.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 372: n71.
37.
DelgadoAGuddatiAK. Clinical endpoints in oncology - a primer. Am J Cancer Res2021; 11: 1121–1131.
38.
SavovićJWeeksLSterneJA, et al.Evaluation of the cochrane collaboration’s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev2014; 3: 37.
39.
HigginsJPAltmanDGGøtzschePC, et al.The cochrane collaboration’s tool for assessing risk of bias in randomised trials. Br Med J2011; 343: d5928.
40.
GuyattGHOxmanADVistGE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J2008; 336: 924–926.
41.
HozoSPDjulbegovicBHozoI. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol2005; 5: 13.
42.
HigginsJPTThomasJChandlerJ, et al.Cochrane handbook for systematic reviews of interventions. 2nd ed. UK: John Wiley & Sons, 2019.
43.
BaselgaJCamponeMPiccartM, et al.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med2012; 366: 520–529.
44.
PiccartMHortobagyiGNCamponeM, et al.Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol2014; 25: 2357–2362.
45.
BaselgaJImSAIwataH, et al.Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2017; 18: 904–916.
46.
BursteinHJCirrincioneCTBarryWT, et al.Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (alliance). J Clin Oncol2014; 32: 3959–3966.
47.
FinnRSCrownJPLangI, et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol2015; 16: 25–35.
48.
FinnRSBoerKBondarenkoI, et al.Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat2020; 183: 419–428.
49.
FinnRSMartinMRugoHS, et al.Palbociclib and letrozole in advanced breast cancer. N Engl J Med2016; 375: 1925–1936.
50.
MukaiHShimizuCMasudaN, et al.Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int J Clin Oncol2019; 24: 274–287.
51.
GelmonKACristofanilliMRugoHS, et al.Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Breast J2020; 26: 368–375.
52.
HortobagyiGNStemmerSMBurrisHA, et al.Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med2016; 375: 1738–1748.
53.
KropIEMayerIAGanjuV, et al.Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol2016; 17: 811–821.
54.
JiangZLiWHuX, et al.Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2019; 20: 806–815.
55.
JohnstonSBasikMHeggR, et al.Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. Breast Cancer Res Treat2016; 160: 91–99.
56.
MartínMLoiblSVon MinckwitzG, et al.Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol2015; 33: 1045–1052.
57.
MusolinoACamponeMNevenP, et al.Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res2017; 19: 18.
58.
SlamonDJNevenPChiaS, et al.Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol2018; 36: 2465–2472.
59.
SlamonDJNevenPChiaS, et al.Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol2021; 32: 1015–1024. Erratum in: Ann Oncol 2021; 32(10): 1307.
60.
ToiMInoueKMasudaN, et al.Abemaciclib in combination with endocrine therapy for east Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci2021; 112: 2381–2392.
61.
GoetzMPToiMCamponeM, et al.MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol2017; 35: 3638–3646.
62.
XuBHuXLiW, et al.Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: primary results from PALOMA-4. Eur J Cancer2022; 175: 236–245.
63.
YardleyDAHartLFavretA, et al.Efficacy and safety of ribociclib with letrozole in US patients enrolled in the MONALEESA-2 study. Clin Breast Cancer2019; 19: 268–277.
64.
ZamanKWinterhalderRMamotC, et al.Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer2015; 51: 1212–1220.
65.
ZhangQYSunTYinYM, et al.MONARCH Plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol2020; 12: 1758835920963925.
66.
CardosoFCostaASenkusE, et al.3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol2017; 28: 16–33 ± 33.
67.
RashaFSharmaMPruittK. Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol2021; 532: 111322.
68.
EllisLMBernsteinDSVoestEE, et al.American Society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol2014; 32: 1277–1280.
69.
LauKHTanAMShiY. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci2022; 23: 2288.
70.
MaduCOWangSMaduCO, et al.Angiogenesis in breast cancer progression, diagnosis, and treatment. J Cancer2020; 11: 4474–4494.
71.
KimHJBaeSC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res2011; 3: 166–179.
72.
SunYHongHJNingZ, et al.Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front Pharmacol2022: 13: 932914.
